Clinical trials: Non Small Cell Lung Cancer Stage IIIB
Non - Small Cell Lung Cancer NSCLC
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of…
- Trial name
- ARCTIC (NCT02352948)
- Testing
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine
- Where
- 201 sites in United States, Australia and 24 more
- Volunteers
- 597 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study will provide treatment with erlotinib to participants with advanced NSCLC who have received at least one course of standard chemotherapy or radiation therapy, or who are not medically suitable for either.
- Trial name
- NCT00949910
- Testing
- Erlotinib
- Where
- 543 sites in Albania, Argentina and 49 more
- Volunteers
- 6,586 people
- Sponsor
- Hoffmann-La Roche
Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
This phase Ib/II trial studies the side effects and best dose of EMB-01 when given together with osimertinib in patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (advanced or…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05498389
- Testing
- EMB-01, Osimertinib
- Where
- 3 sites in United States, China
- Volunteers
- 115 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Stage IIIb Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
To determine whether tariquidar + combined first-line chemotherapy of paclitaxel/carboplatin in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly improve overall survival compared with…
- Trial name
- NCT00042302
- Testing
- Chemotherapy, tariquidar + paclitaxel/carboplatin
- Volunteers
- 540 people
- Sponsor
- QLT Inc.
Non-Small Cell Lung Cancer
A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus
The purpose of this observational study is to estimate the overall survival (OS) rates in the overall study population treated with nivolumab in the second and third line setting in real world clinical practice in Greece and…
- Trial name
- LUCENCE (NCT05034926)
- Where
- 2 sites in Cyprus, Greece
- Volunteers
- 212 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with carboplatin and paclitaxel, and to assess the pharmacokinetics of CS-7017 in…
- Trial name
- NCT01199055
- Testing
- CS-7017, Carboplatin, Paclitaxel
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Carcinoma, Non-Small-Cell Lung
BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)
The objectives of this trial are to estimate the following in Japanese patients with advanced NSCLC of stage IIIB/IV or with recurrence after failure of first-line chemotherapy.
- Trial name
- NCT00979576
- Testing
- BIBF 1120 M + Pemetrexed, BIBF 1120 H + Pemetrexed, BIBF 1120 RD + Pemetrexed
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Stage IIIB or IV Non-Small Cell Lung Cancer
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin
- Trial name
- NCT00473889
- Testing
- vorinostat, Comparator: paclitaxel, Comparator: carboplatin
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase 1/2 multi-center open-label study of BGB324 (bemcentinib) as a single agent (Run-in Cohort) and in combination with erlotinib (Arms A, B, and C) in participants with Stage IIIb or Stage IV non-small cell lung cancer…
- Trial name
- NCT02424617
- Testing
- Erlotinib, Bemcentinib
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- BerGenBio ASA
Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV
The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT00516685)
- Testing
- Recombinant Human rEGF-P64K/Montanide Vaccine
- Where
- 10 sites in Malaysia
- Volunteers
- 230 people
- Sponsor
- Bioven Sdn. Bhd.
Non-small Cell Lung Cancer
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
- Trial name
- NCT04616209
- Testing
- donor-derived NK cell infusion
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Precision Biotech Taiwan Corp.
NSCLC
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
This is a multicenter, open-label, randomised, phase III study of 2 cycles of oral vinorelbine in combination with cisplatin concurrently with radiotherapy randomised to either two more cycles of consolidation therapy with oral…
- Trial name
- NCT00683514
- Testing
- Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
- Where
- Germany
- Volunteers
- 201 people
- Sponsor
- Pierre Fabre Medicament
Advanced Non-Small Cell Lung Cancer
Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine whether S-1 in combination with Cisplatin is effective as 1st line therapy in slowing tumor activity in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00651833
- Testing
- S-1
- Volunteers
- 60 people
- Sponsor
- Taiho Oncology, Inc.
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lung Cancer
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00431015
- Testing
- IPI-504
- Where
- 11 sites in United States
- Volunteers
- 88 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Lung Cancer
Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Marimastat may stop the growth of non-small cell lung cancer by stopping blood flow to the tumor. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of marimastat in treating patients who…
- Trial name
- NCT00002911
- Testing
- marimastat
- Where
- 50 sites in United States, Canada
- Sponsor
- ILEX Oncology Services, Incorporated
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
This study will evaluate the efficacy and safety of sequential administration of Tarceva and gemcitabine/platinum chemotherapy in patients with stage IIIb/IV non-small cell lung cancer.
- Trial name
- NCT01998919
- Testing
- erlotinib [Tarceva], gemcitabine, cisplatin
- Where
- 19 sites in Australia, China and 6 more
- Volunteers
- 154 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response.
- Trial name
- TroFuse-019 (NCT06312137)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Cisplatin
- Where
- 270 sites in United States, Argentina and 29 more
- Volunteers
- 780 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU 201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell…
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer
- Trial name
- NCT04432207
- Testing
- IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3
- Where
- 6 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Imugene Limited
Carcinoma, Non-Small-Cell Lung
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
- Trial name
- NCT00059722
- Testing
- ZD6474, ZD1839
- Where
- 48 sites in United States, Argentina and 4 more
- Volunteers
- 160 people
- Sponsor
- Genzyme, a Sanofi Company